Continued bleeding or early rebleeding is associated with a poor prognosis in patients with variceal haemorrhage. It is not clear why bleeding stops in some patients and continues or restarts in others. It is suggested that secondary haemodynamic changes in the splanchnic circulation after a bleed may contribute to the risk of further bleeding. These changes include the effects of hypotension on portocollateral resistance, the effects of blood in the gut on splanchnic blood flow, and the effects of blood volume expansion on portal venous pressure during resuscitation. These factors, working in concert, cause a secondary rise in portal venous pressure, which may precipitate further bleeding. Treatment aimed at preventing these secondary haemodynamic changes may be beneficial. It is probable that somatostatin and octreotide could act in this way, which may explain their therapeutic efficacy.
Bleeding from oesophageal varices is a common cause of death in patients with cirrhosis and portal hypertension.' Treatment is aimed at stopping the bleeding and preventing rebleeding. Early rebleeding occurs more frequently from varices than from peptic ulcer disease (about 60% v 20%) and usually occurs in the hours and days immediately after the initial bleed.24 Both bleeding that continues despite adequate treatment, and early rebleeding, are associated with a poor prognosis.2 3 Rebleeding and death are more common in patients with severely decompensated liver disease, alcoholic liver disease, and thrombocytopenia. The factors that sustain bleeding and that cause early rebleeding in individual patients are not well understood. 5 Data are accumulating that leads us to suggest that changes in splanchnic blood flow after an initial bleed may contribute to the risk of further variceal bleeding. Treatment aimed at preventing or reversing these secondary haemodynamic changes may lead to better control of bleeding and improved prognosis.
Risk factors for rebleeding and death in variceal haemorrhage There are now a large number of prospective studies looking at patients with portal hypertension and a number of risk factors for bleeding, rebleeding, and death have been identified. The most important risk factor is the severity of the underlying liver disease. It has been shown repeatedly that patients with decompensated liver disease bleed more often and have a worse prognosis than patients with compensated liver disease.5 6 Deterioration of liver function in hospital as a consequence of bleeding may be a further risk factor. It is possible that expeditious treatment to stop bleeding may favourably influence prognosis. 7 In cirrhotic patients the prognosis is also worse in the presence of concomitant alcoholic hepatitis, hepatocellular carcinoma or portal venous thrombosis.8-10 The importance of liver function is underlined by the fact that prognosis is generally much better in patients without significant liver impairment, such as portal venous thrombosis or idiopathic portal hypertension. 1 ' 12 Although the degree of liver dysfunction is of over-riding importance in determining prognosis it is not clear why bleeding occurs unpredictably in individual patients. Other factors, in addition to liver function must be involved. Bleeding is more common in patients with large varices and in patients with greater curve fundal varices. 5 time of a variceal bleed and that the height of the portal venous pressure during a bleeding episode is an important risk factor for rebleeding and mortality.
The rationale for using drugs such as vasopressin and glypressin for active bleeding is based on the assumption that the height of the portal venous pressure is important in maintaining or precipitating variceal haemorrhage. But it is important to realise that portal venous pressure is a dynamic variable, which is determined by the combination of splanchnic blood inflow and the resistance to portal venous outflow, through both the liver and the collateral circulation. Thus portal venous pressure could be raised by increasing splanchnic blood flow or increasing portocollateral vascular resistance, or both.
Splanchnic circulatory changes after bleeding in portal hypertensive animals Experiments in animal models of portal hypertension have suggested that the splanchnic circulation may respond to hypovolaemia and resuscitation in an unusual way.2425 During haemorrhage the expected fall of about 30% in portal venous pressure occurred, but after blood volume restitution portal venous pressure rose significantly to values about 20% higher than baseline pressures. This 'overshoot' occurred despite unchanged splanchnic blood inflow and was attributed to increased resistance in the portocollateral vessels. The investigators speculated that release of vasoactive mediators during the period of hypovolaemia may be responsible. It is not known if similar changes also occur in humans.
Factors that may increase splanchnic blood flow after variceal haemorrhage in humans There are at least two factors which, theoretically, may increase splanchnic blood inflow and thus portal venous pressure after a bleed: (a) over transfusion and (b) the effects of blood in the gut on splanchnic blood flow.
Overtransfusion -blood volume expansion increases portal venous pressure in humans with cirrhosis.26 27 
but probably entail the intestinal nerves and the release of gastrointestinal peptides that may act in an endocrine or a paracrine fashion.32 33 
Hypothesis
We think that the events shown in the Figure may occur, sequentially or simultaneously, after a variceal bleed and adequate resuscitation. After resuscitation there may be an increase in resistance to portal blood flow and a consequent increase in portal venous pressure. The presence of blood in the gut may then cause reflex splanchnic hyperaemia with increased blood flow into the portal venous system. The combination of increased blood flow and increased resistance would result in a further rise in portal venous pressure, which may precipitate further variceal bleeding. If the patient is overtransfused these changes may be magnified. A vicious cycle may be established where bleeding, hypovolaemia, and subsequent resuscitation increase the chances of further bleeding.
Therapeutic implications
To date emergency pharmacological treatment of variceal bleeding has focused primarily on lowering portal venous pressure.34 If our hypothesis is correct, treatment aimed at preventing or ameliorating the secondary changes in splanchnic haemodynamics may also be useful. One therapeutic option would be to remove the blood from the gastrointestinal tract as quickly as possible to prevent secondary splanchnic hyperaemia. In this context it is interesting that a French trial reported that whole gut irrigation with isotonic mannitol reduced blood transfusion requirements and death rates in cirrhotic patients with gastrointestinal bleeding.35
An alternative approach would be to suppress the secondary haemodynamic changes by pharmacological means. We believe that somatostatin and its long acting analogue octreotide may act in this way. There is a growing body of evidence to suggest that both drugs are effective in the emergency treatment of bleeding varices.3"0 Both somatostatin and octreotide seem to have little direct effect on the splanchnic arteries but are believed to work by inhibiting the release of endogenous vasodilator substances, such as glucagon. [41] [42] [43] [44] [45] Using duplex Doppler ultrasound, octreotide has been shown to prevent or inhibit meal related splanchnic hyperaemia in normal subjects.46 47 In cirrhotic patients with portal hypertension octreotide prevented postprandial splanchnic hyperaemia and the associated increase in portal venous pressure. 48 49 In portal hypertensive rats octreotide given after bleeding reduced collateral blood flow and prevented the increase in collateral blood flow after resuscitation. 50 We suggest that somatostatin and its analogues may also act to prevent the release of vasoactive peptides and the associated splanchnic hyperaemia after a variceal bleed. As a consequence they may prevent further rises in portal venous pressure and thus reduce the risk of early rebleeding.
In conclusion, we suggest that changes in splanchnic haemodynamics after a variceal bleed in patients with portal hypertension may contribute to the high risk of continued bleeding and early rebleeding. The effects of hypotension, resuscitation, and blood in the gut may combine to increase splanchnic blood flow and portal venous pressure after a bleed. To date, emergency pharmacological treatment of variceal bleeding has concentrated on reducing portal venous pressure. We suggest that treatment aimed at preventing rises in portal venous pressure after a bleed may also be an effective strategy.
